Risperidone市场－全球产业规模、份额、趋势、机会、预测：按给药途径、应用、最终用户、地区和竞争对手划分，2021-2031年

全球Risperidone市场预计将从 2025 年的 63.6 亿美元成长到 2031 年的 85.8 亿美元，复合年增长率为 5.12%。

Risperidone是一种非典型抗精神病药物，主要用于治疗思觉失调症、躁郁症和自闭症相关过敏症。精神疾病诊断率的提高和学名药价格的下降推动了市场稳定，进而促进了全球医疗保健系统对该药物的广泛应用。此外，利培酮在稳定成人和儿童患者的急性躁郁症发作和精神病发作方面的确切疗效预计将持续推动市场需求。

然而，市场成长面临的主要障碍在于患者的依从性。体重增加和运动障碍等副作用常常会影响患者的依从性。这些安全隐患促使处方医师越来越倾向于选择更新、耐受性更好的替代药物。根据国际药品製造商协会联合会（IFPMA）预测，到2024年，全球将有约10亿人受到精神疾病的影响。如此庞大的患者群体凸显了对Risperidone等现有治疗方法的迫切需求，即便麵临来自新型治疗方法的激烈竞争。

市场驱动因素

全球思觉失调症和双相情感障碍盛行率的上升是Risperidone全球市场的主要驱动因素，这些疾病需要持续的药物治疗来控制慢性症状。随着患者人数的增加，医疗保健系统面临越来越大的压力，需要确保患者能够获得抗精神病药物治疗，以减轻严重精神疾病的社会影响。美国药物滥用和精神健康服务部于2025年7月发布的《2024年全国药物滥用和健康调查》数据显示，到2024年，美国约有1460万成年人患有严重精神疾病，这凸显了对有效治疗方案的巨大需求。这种日益加重的疾病负担与Risperidone等常用抗精神病药物处方量的增加直接相关。

同时，市场正随着长效注射剂型的日益普及而不断发展，旨在提高患者依从性并最大限度地降低因不规律口服给药而导致的复发率。製药公司正抓住这转变机会，部署能够提供持续疗效的先进给药系统。例如，Teva製药在2025年1月发布的2024年第四季及全年财报中指出，其长效Risperidone注射剂Uzedi在2024年的全球销售额已达到1.17亿美元，超出预期。这种向先进製剂的转变在新兴市场也十分明显，路易製药集团（Louillet Pharma Group）报告称，其中枢神经系统产品组合（包括Risperidone微球製剂Likind）在2025年上半年的销售额增长了5.4%。

市场挑战

Risperidone市场的扩张直接受到副作用的阻碍，尤其是体重增加和运动功能障碍等安全隐患。这些生理反应往往会降低患者的药物顺从性，并成为持续用药的一大障碍。当患者出现显着的代谢变化或不自主肌肉收缩时，他们通常会停止治疗或要求调整用药方案。因此，医疗专业人员被迫寻求耐受性更好的替代疗法，导致Risperidone等现有疗法的依赖性和市场份额下降。

向新一代抗精神病药物的转变源自于临床上持续控制症状且避免产生严重副作用的需求。此疾病的广泛流行凸显了这一问题的严重性，因为患者需要持续治疗。世界卫生组织（WHO）在2024年报告称，全球约有2400万人患有思觉失调症，儘管治疗的连续性至关重要，但仍有大规模一部分患者因药物不耐受而中断治疗。因此，更安全的替代药物的存在限制了Risperidone的获利能力，因为医生在处方选择中越来越重视病人的生活品质和用药依从性。

市场趋势

每週一次的口服胃滞留胶囊的研发是一项重要的技术突破，旨在弥合每日口服药物依从性和侵入性注射疗法之间的差距。这种创新製剂采用了一种新型剂型，可滞留在胃中并在七天内持续释放药物，从而有效减轻了思觉失调症患者的用药负担，而用药负担往往是阻碍治疗成功的因素。此方法无需注射即可维持稳定的血浆药物浓度，既解决了用药依从性问题，也尊重了病人的自主权。根据HMP全球学习网络2025年6月发布的题为「新型长效口服Risperidone製剂在3期临床试验中临床实验出令人鼓舞的结果」的报导，STARLYNG-1试验中每週一次的胶囊LYN-005维持了治疗浓度，在第5週时，其最低浓度几何平均比值达到1.04，高于每日一次的速释Risperidone。

同时，非专利注射剂仿製药的推出正在改变市场竞争格局，为长期使用的品牌微球製剂提供了一种价格更实惠的替代方案。标准长效抗精神病药物的复杂非专利药的核准和上市，打破了原厂药曾经享有的市场垄断地位，从而显着降低了价格，并扩大了支付方和患者的用药范围。这种转变迫使品牌药生产商专注于新的给药技术，而学名药则在成熟的注射剂市场中不断扩大市场份额。例如，2025年11月，鲁宾公司在其题为《鲁宾推出Risperidone缓释悬浮液非专利药》的报告中宣布，将在美国推出学名药，目标市场规模约为1.87亿美元。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球Risperidone市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 给药途径（注射、口服、肠外给药）
  • 依病症分类（思觉失调症、躁郁症、泛自闭症障碍相关的易怒等）
  • 依最终使用者（医院、居家医疗、专科诊所、门诊手术中心等）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美Risperidone市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲Risperidone市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：Risperidone在亚太地区的市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：Risperidone在中东和非洲的市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：Risperidone在南美洲的市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球Risperidone市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Otsuka Pharmaceutical Co., Ltd
• AbbVie Inc
• Dr. Reddy's Laboratories Ltd
• Pfizer Inc
• Endo International plc
• Teva Pharmaceutical Industries Ltd
• Sun Pharmaceutical Industries Ltd
• Viatris Inc
• Novartis AG
• Lupin Limited

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Risperidone Market is projected to expand from USD 6.36 Billion in 2025 to USD 8.58 Billion by 2031, reflecting a CAGR of 5.12%. As an atypical antipsychotic, risperidone is primarily employed in the management of schizophrenia, bipolar disorder, and autism-related irritability. Market stability is largely underpinned by increasing diagnostic rates for psychiatric conditions and the affordability of generic versions, which facilitates widespread access across healthcare systems worldwide. Additionally, the drug's proven effectiveness in stabilizing acute manic or psychotic episodes in both adult and pediatric patients ensures continuing demand.

However, market growth encounters a substantial hurdle regarding patient adherence, often compromised by adverse reactions such as weight gain and movement disorders. These safety concerns frequently lead prescribers to favor newer generation alternatives that offer improved tolerability. According to the International Federation of Pharmaceutical Manufacturers and Associations, mental health conditions impacted nearly one billion individuals globally in 2024. This extensive patient population underscores the urgent requirement for accessible treatments like risperidone, even amidst strong competitive pressure from novel therapeutic options.

Market Driver

The rising global prevalence of schizophrenia and bipolar disorder serves as a major engine for the Global Risperidone Market, requiring continuous pharmacological support to control chronic symptoms. As patient numbers grow, healthcare systems face increasing pressure to ensure the availability of antipsychotic therapies to alleviate the societal impact of severe psychiatric illnesses. Data from the Substance Abuse and Mental Health Services Administration in July 2025, referencing the '2024 National Survey on Drug Use and Health', indicates that approximately 14.6 million adults in the United States were identified as having a serious mental illness in 2024, highlighting the immense need for effective therapeutic solutions. This growing disease burden correlates directly with higher prescription rates for established antipsychotics such as risperidone.

Simultaneously, the market is evolving through the increased uptake of long-acting injectable formulations aimed at improving patient compliance and minimizing relapse rates linked to inconsistent oral dosing. Pharmaceutical developers are leveraging this shift by launching advanced delivery systems that provide extended-release benefits. For example, Teva Pharmaceutical Industries reported in its January 2025 'Fourth Quarter and Full Year 2024 Financial Results' that global revenue for UZEDY, its extended-release risperidone injectable, hit $117 million in 2024, exceeding initial expectations. This transition toward advanced formulations is also apparent in emerging markets; Luye Pharma Group noted in 2025 that revenue from its central nervous system portfolio, including the risperidone microsphere Rykindo, rose by 5.4% in the first half of the year.

Market Challenge

Expansion of the risperidone market is directly impeded by safety issues involving adverse effects, particularly weight gain and movement disorders. These physical reactions often lead to suboptimal patient compliance, forming a significant obstacle to sustained usage. When patients undergo considerable metabolic shifts or involuntary muscle contractions, they frequently stop treatment or demand adjustments to their medication plans. Consequently, healthcare providers are compelled to explore alternative therapies with better tolerability, thereby diminishing the reliance on and market share of established options like risperidone.

The trend toward newer generation antipsychotics is driven by the clinical necessity to manage symptoms consistently without causing debilitating side effects. The scale of this issue is highlighted by the widespread prevalence of conditions needing ongoing care; the World Health Organization reported in 2024 that schizophrenia affects roughly 24 million people worldwide, a large demographic for whom treatment continuity is vital but often disrupted by drug intolerance. As a result, the existence of safer pharmacological alternatives constrains risperidone's revenue potential, as physicians increasingly emphasize patient quality of life and adherence when making prescribing choices.

Market Trends

The creation of Once-Weekly Oral Gastric-Resident Capsules represents a significant technological breakthrough aimed at closing the gap between daily oral compliance and invasive injectable treatments. This innovation utilizes a novel dosage form that remains in the stomach to release medication steadily over a seven-day span, effectively reducing the pill burden that often hinders treatment success in schizophrenia patients. By sustaining stable plasma levels without requiring injections, this approach tackles adherence issues while respecting patient autonomy. According to the HMP Global Learning Network in June 2025, the article 'Novel Long-Acting Oral Formulation of Risperidone Shows Promise in Phase 3 Trial' reported that the investigational weekly capsule LYN-005 maintained therapeutic concentrations in the STARLYNG-1 study, reaching a geometric mean ratio for minimum concentration of 1.04 at week five relative to daily immediate-release risperidone.

Concurrently, the introduction of Generic Extended-Release Injectables is altering the competitive environment by offering affordable alternatives to long-established branded microsphere products. The approval and release of complex generic variants of standard long-acting antipsychotics are breaking the market exclusivity once enjoyed by originator drugs, leading to substantial price reductions and broader access for payers and patients. This transition compels branded manufacturers to focus on newer delivery technologies, while generics seize market share in the mature injectable sector. For instance, Lupin Limited announced in November 2025, within its 'Lupin Launches Generic Risperidone Extended-Release Injectable Suspension' report, that it had released its generic option in the United States, aiming for a total annual addressable market valued at roughly $187 million.

Key Market Players

• Otsuka Pharmaceutical Co., Ltd
• AbbVie Inc
• Dr. Reddy's Laboratories Ltd
• Pfizer Inc
• Endo International plc
• Teva Pharmaceutical Industries Ltd
• Sun Pharmaceutical Industries Ltd
• Viatris Inc
• Novartis AG
• Lupin Limited

Report Scope

In this report, the Global Risperidone Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Risperidone Market, By Route Of Administration

• Injectable
• Oral
• Parenteral

Risperidone Market, By Application

• Schizophrenia
• Bipolar Disorder
• Irritability Associated with Autistic Disorder
• Others

Risperidone Market, By End-Users

• Hospitals
• Homecare
• Specialty Clinics
• Ambulatory Surgical Centers
• Others

Risperidone Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Risperidone Market.

Available Customizations:

Global Risperidone Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Risperidone Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Route Of Administration (Injectable, Oral, Parenteral)
  • 5.2.2. By Application (Schizophrenia, Bipolar Disorder, Irritability Associated with Autistic Disorder, Others)
  • 5.2.3. By End-Users (Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Risperidone Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Route Of Administration
  • 6.2.2. By Application
  • 6.2.3. By End-Users
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Risperidone Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Route Of Administration
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End-Users
  • 6.3.2. Canada Risperidone Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Route Of Administration
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End-Users
  • 6.3.3. Mexico Risperidone Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Route Of Administration
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End-Users

7. Europe Risperidone Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Route Of Administration
  • 7.2.2. By Application
  • 7.2.3. By End-Users
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Risperidone Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Route Of Administration
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End-Users
  • 7.3.2. France Risperidone Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Route Of Administration
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End-Users
  • 7.3.3. United Kingdom Risperidone Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Route Of Administration
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End-Users
  • 7.3.4. Italy Risperidone Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Route Of Administration
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End-Users
  • 7.3.5. Spain Risperidone Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Route Of Administration
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End-Users

8. Asia Pacific Risperidone Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Route Of Administration
  • 8.2.2. By Application
  • 8.2.3. By End-Users
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Risperidone Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Route Of Administration
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End-Users
  • 8.3.2. India Risperidone Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Route Of Administration
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End-Users
  • 8.3.3. Japan Risperidone Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Route Of Administration
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End-Users
  • 8.3.4. South Korea Risperidone Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Route Of Administration
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End-Users
  • 8.3.5. Australia Risperidone Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Route Of Administration
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End-Users

9. Middle East & Africa Risperidone Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Route Of Administration
  • 9.2.2. By Application
  • 9.2.3. By End-Users
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Risperidone Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Route Of Administration
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End-Users
  • 9.3.2. UAE Risperidone Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Route Of Administration
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End-Users
  • 9.3.3. South Africa Risperidone Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Route Of Administration
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End-Users

10. South America Risperidone Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Route Of Administration
  • 10.2.2. By Application
  • 10.2.3. By End-Users
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Risperidone Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Route Of Administration
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End-Users
  • 10.3.2. Colombia Risperidone Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Route Of Administration
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End-Users
  • 10.3.3. Argentina Risperidone Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Route Of Administration
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End-Users

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Risperidone Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Otsuka Pharmaceutical Co., Ltd
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. AbbVie Inc
• 15.3. Dr. Reddy's Laboratories Ltd
• 15.4. Pfizer Inc
• 15.5. Endo International plc
• 15.6. Teva Pharmaceutical Industries Ltd
• 15.7. Sun Pharmaceutical Industries Ltd
• 15.8. Viatris Inc
• 15.9. Novartis AG
• 15.10. Lupin Limited

16. Strategic Recommendations

17. About Us & Disclaimer